Author

M. M. Allevato

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

J. S. Gutkind· 3 shared Z. Wang· 3 shared A. A. Molinolo· 2 shared E. E. W. Cohen· 2 shared V. H. Wu· 2 shared Y. Goto· 2 shared A. B. Sharabi· 1 shared A. B. Simon· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. S. Gutkind

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivAug 7, 2023

A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC

Y. Goto, K. Koshizuka, T. Ando…·J. S. Gutkind

This study identifies mTOR inhibition as a way to prevent adaptive resistance to CDK4/6 blockade in HNSCC by targeting cell cycle pathways.

DOI 10.1158/2767-9764.crc-24-0247

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivFeb 1, 2022

Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC

R. Saddawi-Konefka, A. O'Farrell, F. Faraji…·J. S. Gutkind

This study shows that lymphatic-preserving treatment sequences enhance cDC1-dependent antitumor immunity in HNSCC by avoiding lymphablation, which compromises ICI response.

DOI 10.1038/s41467-022-31941-w

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJun 15, 2019

Novel syngeneic animal model of tobacco-associated oral cancer reveals the activity of in situ anti-CTLA-4

Z. Wang, V. H. Wu, M. M. Allevato…·J. S. Gutkind

This paper develops a syngeneic mouse model of tobacco-associated HNSCC that shows high response rates to anti-CTLA-4 therapy.

DOI 10.1101/672527

mousebulk RNA-seq

𝕏 PostBluesky